Copyright
©The Author(s) 2020.
World J Transplant. Nov 28, 2020; 10(11): 356-364
Published online Nov 28, 2020. doi: 10.5500/wjt.v10.i11.356
Published online Nov 28, 2020. doi: 10.5500/wjt.v10.i11.356
Table 1 Outcome measures
| Outcome measures | Documented visits reviewed: | Documented visits reviewed: | ||||
| 6 mo, mean (SD) | 4 mo, mean (SD) | 2 mo, mean (SD) | 2 mo, mean (SD) | 4 mo, mean (SD) | 6 mo, mean (SD) | |
| Tacrolimus dose (mg/kg/d) | 0.13 (0.04) | 0.12 (0.05) | 0.11 (0.05) | 0.09 (0.05)1 | 0.07 (0.03)1 | 0.06 (0.03)1 |
| Tacrolimus blood levels (ng/mL) | 7.4 (2.6) | 7.4 (2.5) | 7.4 (2.6) | 8.8 (4.9) | 6.9 (3.6) | 6.8 (3.2) |
| eGFR (1.73 mL/min/1.73 m2) | ---- | ---- | 69.2 (29.7)1 | 63.6 (21.4) | 64.2 (2.10) | 71.2 (27.6)1 |
- Citation: Méndez S, Ramay BM, Aguilar-González A, Lou-Meda R. Exploring the safety and efficacy of adding ketoconazole to tacrolimus in pediatric renal transplant immunosuppression. World J Transplant 2020; 10(11): 356-364
- URL: https://www.wjgnet.com/2220-3230/full/v10/i11/356.htm
- DOI: https://dx.doi.org/10.5500/wjt.v10.i11.356